^
Association details:
| Biomarker: | AKT2 expression |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | CCT128930 (AKT inhibitor, p70S6K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Akt2 Mediates Glucocorticoid Resistance in Acute Lymphoblastic Leukemia through FoxO3a/Bim Axis and Serves As a Direct Target for Resistance Reversal
Published date:
11/01/2018
Excerpt:
By western blot analysis we observed the expression of Akt2 in intrinsically resistant T-ALL cells....Selective inhibition of Akt2 with CCT128930 more significantly enhances the FoxO3a/Bim signaling pathway, increases DEX-mediated killing of resistant T-ALL cells (F) and effectively reverses GC resistance than Akt1 inhibitor in vitro and in vivo.
DOI:
https://doi.org/10.1182/blood-2018-99-110496
